Reversal of Endocrinopathies in Transfusional Iron Overload patients-the next frontier in Iron chelation

European journal of Clinical and Medical Oncology

Volumn 2, Issue 4, 2010, Pages

  Farmaki, Kallistheni ^a   Berdoukas, Vasilios ^b  

^a General Hospital of Corinth   (Greece)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Deferasirox; Deferiprone; Desferrioxamine; Endocrine disorders; Magnetic resonance imaging; Thalassemia major

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON; REACTIVE OXYGEN METABOLITE; THYROXINE;

AMENORRHEA; ARTICLE; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MORBIDITY; NONHUMAN; OVERALL SURVIVAL; THALASSEMIA;

EID: 79956083944     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009 May- Jun;42(3):247-251.
2. Telfer PT, Warburton F, Christou S, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009 Dec;94(12):1777-1778.
3. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood. 2004 Jul 1;104(1): 34-39.
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004 Oct;89(10):1187-1193.
5. De Sanctis V, Eleftheriou A, Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004 Dec;2(Suppl. 2):249-255.
6. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev. 2007 Dec;5(2):642-648.
7. Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa MR. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev. 2004 Dec;2(Suppl. 2):285-291.
8. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003 Oct 1;102(7):2670-2677.
9. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005 Dec;57(4):547-583.
10. Crichton RR, Ward RJ. Iron chelators and their therapeutic potential. Met Ions Biol Syst. 2004;41:185-219.
11. Hershko C, Abrahamov A, Konijn AM, et al. Objectives andmethods of iron chelation therapy. Bioinorg Chem Appl. 2003:151-168.
12. Caro JJ, Ward A, Green TC, et al. Impact of thalassemia major on patients and their families. Acta Haematol. 2002;107(3):150-157.
13. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
14. De Sanctis V. Growth and puberty and its management in thalassaemia. Horm Res. 2002;58(Suppl. 1):72-79.
15. Raiola G, Galati MC, De Sanctis V, et al. Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab. 2003 Mar;16 (Suppl. 2):259-266.
16. De Sanctis V, Borsari G, Brachi S, Govoni M, Carandina G. Spermatogenesis in young adult patients with beta-thalassaemia major long-term treated with desferrioxamine. Georgian Med News. 2008 Mar(156):74-77.
17. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004 Nov;127(3):348-355.
18. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998 Nov;103(2):361-364.
19. Grady R, Berdoukas V, Rachmielewitz EA, Giardina PJ. Optimising chelation therapy: Combining deferiprone and deferoxamine. Blood 2000, 96:604a.
20. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003 May;88(5):489-496.
21. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemiamajor. Blood. 2006 May 1;107(9):3733-3737.
22. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002 Aug 17; 360(9332):516-520.
23. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006 May 1;107(9):3738-3744.
24. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003 Jul 1;102(1):17-24.
25. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003 Sep 1;102(5):1583-1587.
26. Heinz HH, Acklin P, Faller B, Lattmann R, Schnebli HP. 4-[3,5-Bis(2- hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel efficient and selective iron(III) complexing agent. Angew Chem Int. 1999(Ed 38): 2568-2570.
27. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010 Apr;95(4):557-566.
28. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of -30 mg/kg per d in patients with transfusiondependent anaemia and iron overload. Br J Haematol. 2009 Dec;147(5): 752-759.
29. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010 Jul 29;116(4):537-543.
30. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010 Mar 25;115(12):2364-2371.
31. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006 May 1;107(9):3436-3441.
32. Reported patient deaths increased by 14% in 2009. ISMP Med Saf Alert. 2010;15(12):1-2.
33. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001 Oct;38(4):360-366.
34. Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res. 2010 Aug;156(2):55-67.
35. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica. 2003 Dec;88(12):1423-1425.
36. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010 Feb;148(3):466-475.
37. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001 Feb 15;97(4):1115-1122.
38. Jetsrisuparb A, Komvilaisak P, Wiangnon S, Jetsrisuparb C. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. J Pediatr Hematol Oncol. 2010 Jul;32(5):400-403.
39. Lal A SN, Ng V, Foote D, Neumayer L, Kurio G, Harmatz P, Porter J, Vichinsky E. Safety of Deferasirox and Deferiprone Combined Chelation Therapy in Thalassemia Major Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:4269. 2009.
40. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for ''hard-to-chelate'' beta-thalassemiamajor patients. Am J Hematol. 2010 Jun;85(6):460-461.
41. Berdoukas V, Carson S, Nord A, Dongelyan A, Gavin S, Hofstra TC, et al. Combining two orally active iron chelators for thalassemia. Ann Hematol. 2010 Mar 10.
42. Perera NJ, Lau NS, Mathews S, Waite C, Ho PJ, Caterson ID. Overview of endocrinopathies associated with ss-thalassaemia major. Intern Med J. 2010 May 11.
43. Chatterjee R, Bajoria R. New concept in natural history and management of diabetes mellitus in thalassemia major. Hemoglobin. 2009;33(Suppl. 1):S127-S130.
44. Christoforidis A, Perifanis V, Athanassiou-Metaxa M. Combined chelation therapy improves glucose metabolism in patients with betathalassaemia major. Br J Haematol. 2006 Oct;135(2):271-272.
45. Platis O, Anagnostopoulos G, Farmaki K, Posantzis M, Gotsis E, Tolis G. Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy. Pediatr Endocrinol Rev. 2004 Dec;2(Suppl. 2):279-281.
46. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol. 2006 Aug;134(4):438-444.
47. Melchionda N, Forlani G, Marchesini G, Baraldi L, Natale S. WHO and ADA criteria for the diagnosis of diabetes mellitus in relation to body mass index. Insulin sensitivity and secretion in resulting subcategories of glucose tolerance. Int J Obes Relat Metab Disord. 2002 Jan;26(1):90-96.
48. Clark P, Britton LJ, Powell LW. The diagnosis and management of heredi-tary haemochromatosis. Clin Biochem Rev. 2010 Feb;31(1):3-8.
49. Althausen TL, Doig RK, Weiden S, Motteram R, Turner CN, Moore A. Hemochromatosis; investigation of twenty-three cases, with special reference to etiology, nutrition, iron metabolism, and studies of hepatic and pancreatic function. AMA Arch Intern Med. 1951 Nov;88(5):553-570.
50. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001 Dec;22(23):2171-2179.
51. Hekmatnia A, Radmard AR, Rahmani AA, Adibi A, Khademi H. Magnetic resonance imaging signal reduction may precede volume loss in the pituitary gland of transfusion-dependent beta-thalassemic patients. Acta Radiol. 2010 Feb;51(1):71-77.
52. Zafar AM, Zuberi L, Khan AH, Ahsan H. Utility of MRI in assessment of pituitary iron overload. J Pak Med Assoc. 2007 Sep;57(9):475-477.
53. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009 Nov 5;114(19):4021-4026.
54. Papakonstantinou O, Ladis V, Kostaridou S, et al. The pancreas in betathalassemia major: MR imaging features and correlation with iron stores and glucose disturbances. Eur Radiol. 2007 Jun;17(6):1535-1543.
55. Au WY, Lam WW, Chu WW, et al. Organ-specific hemosiderosis and functional correlation in Chinese patients with thalassemia intermedia and hemoglobin H disease. Ann Hematol. 2009 Oct;88(10):947-950.
56. Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2- channels in iron transport and iron-overload cardiomyopathy. J Mol Med. 2006 May;84(5):349-364.
57. Au WY, Lam WW, Chu W, et al. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemiamajor. Haematologica. 2008 Jan;93(1):116-119.
58. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005 Nov 1;106(9):3242-3250.
59. Angelopoulos NG, Zervas A, Livadas S, et al. Reduced insulin secretion in normoglycaemic patients with beta-thalassaemia major. Diabet Med. 2006 Dec;23(12):1327-1331